Condition
Myasthenic Syndromes, Congenital
Total Trials
4
Recruiting
1
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 15/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
2Total
P 1 (1)
P 3 (1)
Trial Status
Unknown2
Recruiting1
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06630650RecruitingPrimary
A Prospective Natural History and Outcome Measure Validation Study of Congenital Myasthenic Syndromes
NCT01765140UnknownPrimary
Treatment Use of 3,4-Diaminopyridine
NCT02562066Phase 3CompletedPrimary
Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes
NCT00541216Phase 1UnknownPrimary
Ephedrine for the Treatment of Congenital Myasthenia
Showing all 4 trials